indication

Schizophreniform Disorder

Competitive landscape projected to LB-102’s launch window

as of 2026-07-01
Competitive set
9
7 approved · 2 pipeline
Next guided milestone
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiation
LB-102 protection (issued)
2037
+4 pending families to 2047

Projection timeline

actual past → guided future · protection walls overlaid
68 events
2020
2024
2028
2032
2036
2040
2044
2048
today
LB-102 launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 48 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 48 trials
OwnerEli Lilly and Company
Protection2041
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
Phase 43 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 31 trial
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 21 trial
OwnerSumitomo Pharmaceuticals America
Protection2031
drugCompleted
Clozapine
US-approved 1989 · Clozaril
Phase 41 trial
OwnerShanghai Mental Health Center
Protection2028
drugTerminated
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 41 trial
OwnerAstraZeneca
Protection—
drugCompleted
Amisulpride
Pipeline · Phase 4
Phase 43 trials
OwnerShanghai Mental Health Center
Protection2038
drugUnknown
Minocycline
Pipeline · Phase 1
Phase 11 trial
OwnerPakistan Institute of Living and Learning
Protection—

Market size

prevalence as a range, not a number